Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication.
Publication Title
JACC Cardiovasc Interv
Document Type
Article
Publication Date
6-10-2024
Keywords
montana; missoula; Humans; Atrial Appendage; Atrial Fibrillation; Female; Male; Anticoagulants; Aged; Contraindications, Drug; Risk Factors; Registries; Risk Assessment; Aged, 80 and over; Time Factors; Administration, Oral; Ischemic Stroke; Cardiac Catheterization; Treatment Failure; Hemorrhage; Recurrence; Middle Aged; Retrospective Studies; Europe
Abstract
BACKGROUND: Left atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patients with a thrombotic event despite OAT are at high risk for recurrence and may also benefit from LAAO.
OBJECTIVES: This study sought to investigate the efficacy of LAAO in AF patients with a thrombotic event on OAT compared to: 1) LAAO in AF patients with a contraindication for OAT; and 2) historical data.
METHODS: The international LAAO after stroke despite oral anticoagulation (STR-OAC LAAO) collaboration included patients who underwent LAAO because of thrombotic events on OAT. This cohort underwent propensity score matching and was compared to the EWOLUTION (Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology) registry, which represents patients who underwent LAAO because of OAT contraindications. The primary outcome was ischemic stroke. Event rates were compared between cohorts and with historical data without OAT, yielding relative risk reductions based on risk scores.
RESULTS: Analysis of 438 matched pairs revealed no significant difference in the ischemic stroke rate between the STR-OAC LAAO and EWOLUTION cohorts (2.5% vs 1.9%; HR: 1.37; 95% CI: 0.72-2.61). STR-OAC LAAO patients exhibited a higher thromboembolic risk (HR: 1.71; 95% CI: 1.04-2.83) but lower bleeding risk (HR: 0.39; 95% CI: 0.18-0.88) compared to EWOLUTION patients. The mortality rate was slightly higher in EWOLUTION (4.3% vs 6.9%; log-rank P = 0.028). Relative risk reductions for ischemic stroke were 70% and 78% in STR-OAC LAAO and EWOLUTION, respectively, compared to historical data without OAT.
CONCLUSIONS: LAAO in patients with a thrombotic event on OAT demonstrated comparable stroke rates to the OAT contraindicated population in EWOLUTION. The thromboembolic event rate was higher and the bleeding rate lower, reflecting the intrinsically different risk profile of both populations. Until randomized trials are available, LAAO may be considered in patients with an ischemic event on OAT.
Clinical Institute
Cardiovascular (Heart)
Clinical Institute
Neurosciences (Brain & Spine)
Specialty
Cardiology
Specialty
Neurosciences
DOI
10.1016/j.jcin.2024.04.012
Recommended Citation
Aarnink, Errol W; Maarse, Moniek; Fierro, Nicolai; Mazzone, Patrizio; Beneduce, Alessandro; Tondo, Claudio; Gasperetti, Alessio; Pracon, Radoslaw; Demkow, Marcin; Zielinski, Kamil; de Backer, Ole; Korsholm, Kasper; Nielsen-Kudsk, Jens Erik; Estévez-Loureiro, Rodrigo; Caneiro-Queija, Berenice; Benito-González, Tomás; Pérez de Prado, Armando; Nombela-Franco, Luis; Salinas, Pablo; Holmes, David; Almakadma, Abdul H; Berti, Sergio; Romeo, Maria Rita; Millan, Xavier; Arzamendi, Dabit; Alla, Venkata M; Agarwal, Himanshu; Eitel, Ingo; Paitazoglou, Christina; Freixa, Xavier; Cepas-Guillén, Pedro; Chothia, Rashaad; Badejoko, Solomon O; Spoon, Daniel; Maddux, James T; El-Chami, Mikhael; Ram, Pradhum; Branca, Luca; Adamo, Marianna; Suradi, Hussam S; Peper, Joyce; van Dijk, Vincent F; Rensing, Benno J W M; Swaans, Martin J; Vireca, Elisa; Bergmann, Martin W; and Boersma, Lucas V A, "Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication." (2024). Articles, Abstracts, and Reports. 8999.
https://digitalcommons.providence.org/publications/8999
10.1016/j.jcin.2024.04.012
